News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opexa Therapeutics (OPXA) Reports Second Quarter 2014 Financial Results And Provides Corporate Update



8/15/2014 8:29:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of Multiple Sclerosis (MS), today reported financial results for the second quarter ended June 30, 2014 and provided an overview of the Company’s recent corporate developments.

Recent highlights include:

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES